Validation of Simplified Renal Dosimetry Protocols for ¹⁷⁷Lu-DOTATATE Therapy using the IDAC-Dose software
Preprint
- 28 October 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Objective: The multi-time-point imaging method for renal dosimetry in ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) imposes a significant burden on patients. While simplified protocols have been explored, their validation has predominantly relied on legacy MIRD-based software, hindering inter-institutional standardization. This study aimed to provide the first systematic validation of simplified two-time-point (2TP) and three-time-point (3TP) protocols using a modern, open-source, ICRP-compliant platform to establish a foundation for a standardized and accessible methodology. Methods: This retrospective study analyzed data from 17 neuroendocrine neoplasm patients (28 kidneys) who underwent PRRT. Renal absorbed doses were calculated using various 2TP and 3TP combinations derived from a reference four-time-point (4TP) imaging schedule (at 4-, 24-, 72-, and 120-hours post-administration) with the open-source, ICRP-compliant software IDAC-Dose 2.1. The accuracy of each simplified protocol was evaluated against the 4TP reference using mean percent error (MPE), mean absolute percent error (MAPE), root mean square error (RMSE), and Bland-Altman analysis. Results: Protocols including the 120-hour late-phase time point demonstrated significantly higher accuracy. The 2TP (4, 24) protocol was the least accurate, showing a profound underestimation (MPE: -14.3%), high absolute error (MAPE: 29.6%), and the largest overall error (RMSE: 1271.9 mGy). In contrast, the 2TP (24, 120) protocol showed excellent agreement with the reference (MPE: 0.57%, MAPE: 5.5%) with no significant systematic bias. Among the 3TP methods, the 3TP (24, 72, 120) protocol yielded the highest accuracy and precision (MAPE: 1.97%; RMSE: 58.1 mGy). A well-chosen 2TP protocol was more accurate than a poorly chosen 3TP protocol. Conclusions: Accurate and reproducible renal dosimetry in ¹⁷⁷Lu-DOTATATE therapy can be achieved with simplified protocols. The key principle is the strategic inclusion of a late-phase time point (around 120 hours). The 2TP (24, 120) and 3TP (24, 72, 120) combinations are recommended as practical, high-accuracy alternatives. This work provides the foundational evidence for adopting these protocols within a modern dosimetric framework, representing a critical step toward developing internationally standardized and clinically feasible dosimetry for PRRT.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Overview of the 2022 WHO Classification of Neuroendocrine NeoplasmsEndocrine Pathology, 2022
- 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialThe Lancet Oncology, 2021
- Technical Note: Single time point dose estimate for exponential clearanceMedical Physics, 2018
- Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and toleranceActa Oncologica, 2017
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsNew England Journal of Medicine, 2017
- ICRP Publication 133: The ICRP computational framework for internal dose assessment for reference adults: specific absorbed fractionsAnnals of the ICRP, 2016
- Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphyEJNMMI Research, 2012
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapyAmerican Journal of Kidney Diseases, 2001